Mahzi Therapeutics
Private
Clinical-stage biotechnology company developing precision gene therapies for rare genetic neurodevelopmental disorders.
Company Info
Upcoming Milestones & Key Dates
2026-Q4
Regulatory
FDA Rare Pediatric Disease Designation review
Clinical Development Pipeline
MZ-1866
Target: AAV-based gene therapyRecent News
No recent news updates available for this company.
Leadership Team
Arbor Trisal
CEO